Joseph Saba, Chief Executive Officer

Dr. Joseph Saba is Co-Founder and Chief Executive Officer of Axios International. Under his leadership, the company has launched a number of successful drug access programs and developed innovative models for market access and healthcare systems strengthening.

Dr. Saba is a French Lebanese medical doctor specialized in infectious disease, health management and statistics. Throughout his career, he has led numerous discussions with pharmaceutical companies, governments and other key players across the healthcare community to drive access to innovative medications in developing countries and emerging markets. 

In this context, he is known internationally for his expertise in the prevention of mother-to-child transmission of HIV and for establishing the first HIV/AIDS antiretroviral drug access programs in Chile, Côte d’Ivoire, Uganda and Vietnam through the UNAIDS HIV Drug Access Initiative.

In 1993, Dr. Saba joined the World Health Organization (WHO) as the WHO Focal Point for the National Plan for HIV Vaccine Development, and from 1994-1995, he worked with the Global Program on AIDS in the WHO Department of Clinical Research and Drug Development. Following his time at WHO, he worked with the Joint United Nations Program on HIV/AIDS in the Department of Policy, Strategy and Research, where he coordinated the PETRA study – a multi-centre clinical trial on prevention of mother-to-child transmission of HIV/AIDS in three countries in Africa.

Dr. Saba has conducted numerous fieldworks and led various field teams in global health research projects, including a mother-to-child transmission prevention project in Tanzania, South Africa and Uganda, a female condom program in Thailand, and an
epidemiologic survey on HIV patients in Rwanda.

He completed his medical degree, along with a certificate of Medical Statistics, at the
University Paris VI (France). Dr. Saba is also a graduate of St. Joseph University (Beirut, Lebanon) and holds a Master of Communications and Medical Management (MSc) from the Superior Business School (Paris, France). Of Lebanese and French descent, he is fluent in Arabic, French and English.

Dr. Saba has been featured in the Pharmaceutical ExecutiveReutersWall Street Journal, International Herald Tribune and Newsweek, among others.